Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017

• Aim: Following the approval of two new therapeutic combinations within the European Union in 2017, the former Swedish recommendations for the treatment of hepatitis C virus (HCV) infection from 2016 were deemed in need of updating. Materials and methods: An expert meeting to this end was held in Stockholm, Sweden in October 2017. Results and conclusions: An interferon-free combination of direct-acting antiviral agents is now recommended for all patients with chronic HCV infection, regardless of liver fibrosis stage, in order to limit morbidity and spread of the disease. An extended discussion of treatment for people who inject drugs in order to diminish transmission is included.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Infektionsmedicin (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Infectious Medicine (hsv//eng)

Nyckelord

Hepatitis C virus

HCV

Guidelines

Direct-acting antiviral agents

Ribavirin

Genotype

People who inject drugs

PWIDs

Children

Chronic

kidney disease

HIV

Elimination

Eradication

Resistance associated

variants (RAVs)

Resistance associated substitutions (RASs)

genotype 1 infection

daclatasvir plus sofosbuvir

treatment-experienced

patients

treatment-naive patients

severe renal impairment

fixed-dose

combination

open-label

hcv infection

hepatocellular-carcinoma

phase-3 trial

Infectious Diseases

Hepatitis C virus

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)